New drug combo tested for blood cancer patients
NCT ID NCT03984097
Summary
This early-stage study is testing whether adding an experimental drug called TAK-079 to standard multiple myeloma treatments is safe and tolerable. The trial involves about 50 adults with newly diagnosed multiple myeloma who are not planning to get a stem cell transplant right away. Researchers want to find the right dose of TAK-079 to use with standard treatments and check for side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Alabama Oncology
Birmingham, Alabama, 35211, United States
-
American Oncology Partners of Maryland, PA
Bethesda, Maryland, 20817, United States
-
Columbia University Medical Center
New York, New York, 10032, United States
-
Froedtert Hospital & the Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
Good Samaritan Hospital
Cincinnati, Ohio, 45220, United States
-
Levine Cancer Institute
Charlotte, North Carolina, 28204, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Oregon Health & Science University
Portland, Oregon, 97239, United States
-
Pacific Cancer Care
Monterey, California, 93940, United States
Conditions
Explore the condition pages connected to this study.